We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Elevated Levels of Two Protein Biomarkers Indicate Potential for Development of Pre-Eclampsia

By LabMedica International staff writers
Posted on 16 Jul 2020
A pair of novel protein biomarkers has been identified in the blood of asymptomatic pregnant women that can be used to predict the potential onset of pre-eclampsia.

Pre-eclampsia (PE) is a disorder of pregnancy characterized by the onset of high blood pressure and often a significant amount of protein in the urine. More...
When it arises, the condition begins after 20 weeks of pregnancy. In severe disease there may be red blood cell breakdown, a low blood platelet count, impaired liver function, kidney dysfunction, swelling, shortness of breath due to fluid in the lungs, or visual disturbances. Pre-eclampsia increases the risk of poor outcomes for both the mother and the baby. If left untreated, it may result in seizures at which point it is known as eclampsia. Ten to 15% of maternal mortality is associated with pre-eclampsia and eclampsia.

Development of effective prevention and treatment strategies for pre-eclampsia has been limited by the lack of accurate methods for identification of at-risk pregnancies.

In an effort to correct this lack, investigators at the University of Technology Sydney (Australia) evaluated the diagnostic and therapeutic potential for pre-eclampsia of the angiogenesis protein markers, FKBPL-CD44. FKBPL (FKBP prolyl isomerase like) has similarity to the immunophilin protein family, which play a role in immunoregulation and basic cellular processes involving protein folding and trafficking. CD44 is a cell-surface glycoprotein involved in cell-cell interactions, cell adhesion, and migration. It is a receptor for hyaluronic acid (HA) and can also interact with other ligands, such as osteopontin, collagens, and matrix metalloproteinases (MMPs). This protein participates in a wide variety of cellular functions including lymphocyte activation, recirculation and homing, hematopoiesis, and tumor metastasis.

For the current study, the investigators analyzed 57 samples that were pre-diagnosis (15 and 20 weeks’ gestation) and 18 that were post-diagnosis (14 for plasma; four for placenta) of pre-eclampsia for determination of FKBPL and CD44 concentrations, compared to healthy controls.

Results revealed that the CD44/FKBPL ratio was reduced in placenta and plasma following clinical diagnosis of pre-eclampsia. At 20 weeks’ gestation, a high plasma CD44/FKBPL ratio was independently associated with the 2.5-fold increased risk of pre-eclampsia.

"There are two main types of pre-eclampsia: early-onset pre-eclampsia diagnosed before 34 weeks of a pregnancy and late-onset pre-eclampsia diagnosed from 34 weeks onwards," said senior author Dr. Lana McClements, lecturer in biotechnology at the University of Technology Sydney. "The vast majority of the current screening and monitoring strategies are focused on early-onset pre-eclampsia, which comprises only 10-15% of all pre-eclampsia cases, whereas late pre-eclampsia has been largely neglected."

"The biomarkers allow the prediction of irregular placenta or maternal vascular function, which are key underlying causes of pre-eclampsia," said Dr. McClements. "This could lead to the early diagnosis and prevention of severe pre-eclampsia and associated complications including death, therefore also giving insight into disease mechanisms and possible treatment targets."

The study was published in the July 3, 2020, online edition of the Journal of Clinical Endocrinology and Metabolism.

Related Links:
University of Technology Sydney


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Portable Electronic Pipette
Mini 96
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.